MX2017000116A - Moleculas basadas en il-15 y metodos para su uso. - Google Patents
Moleculas basadas en il-15 y metodos para su uso.Info
- Publication number
- MX2017000116A MX2017000116A MX2017000116A MX2017000116A MX2017000116A MX 2017000116 A MX2017000116 A MX 2017000116A MX 2017000116 A MX2017000116 A MX 2017000116A MX 2017000116 A MX2017000116 A MX 2017000116A MX 2017000116 A MX2017000116 A MX 2017000116A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- based molecules
- antibody
- cancer
- invention features
- Prior art date
Links
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 230000002483 superagonistic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pulmonology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La invención incluye terapias combinadas usando un complejo superagonista basado en IL-15 y un anticuerpo para tratar efectivamente sujetos con cáncer y enfermedades infecciosas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462018899P | 2014-06-30 | 2014-06-30 | |
PCT/US2015/038587 WO2016004060A2 (en) | 2014-06-30 | 2015-06-30 | Il-15-based molecules and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017000116A true MX2017000116A (es) | 2017-05-30 |
Family
ID=54929364
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017000116A MX2017000116A (es) | 2014-06-30 | 2015-06-30 | Moleculas basadas en il-15 y metodos para su uso. |
Country Status (11)
Country | Link |
---|---|
US (15) | US9925247B2 (es) |
EP (3) | EP3160498B1 (es) |
JP (4) | JP6842926B2 (es) |
KR (3) | KR20230028807A (es) |
CN (3) | CN112494646A (es) |
AU (4) | AU2015284248B2 (es) |
CA (2) | CA2953816C (es) |
ES (1) | ES2899890T3 (es) |
MX (1) | MX2017000116A (es) |
PL (1) | PL3160498T3 (es) |
WO (1) | WO2016004060A2 (es) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11046747B2 (en) | 2010-09-21 | 2021-06-29 | Altor Bioscience Llc | Multimeric IL-15 soluble fusion molecules and methods of making and using same |
US11053299B2 (en) | 2010-09-21 | 2021-07-06 | Immunity Bio, Inc. | Superkine |
US11173191B2 (en) | 2014-06-30 | 2021-11-16 | Altor BioScience, LLC. | IL-15-based molecules and methods of use thereof |
US11318201B2 (en) | 2016-10-21 | 2022-05-03 | Altor BioScience, LLC. | Multimeric IL-15-based molecules |
US11365231B2 (en) | 2007-05-11 | 2022-06-21 | Altor Bioscience, Llc | Interleukin 15 (IL-15) variants |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2725450T3 (es) | 2007-07-02 | 2019-09-24 | Etubics Corp | Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples |
WO2018112219A1 (en) * | 2016-12-14 | 2018-06-21 | Nant Holdings Ip, Llc | Superkine |
US9605276B2 (en) | 2012-08-24 | 2017-03-28 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
CN113456812B (zh) | 2015-01-09 | 2024-08-20 | 埃图比克斯公司 | 用于联合免疫治疗的方法和组合物 |
KR20170102002A (ko) | 2015-01-09 | 2017-09-06 | 이투빅스 코포레이션 | 에볼라 바이러스 백신접종을 위한 방법 및 조성물 |
US11149087B2 (en) | 2015-04-20 | 2021-10-19 | Etubics Corporation | Methods and compositions for combination immunotherapy |
US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
DK3411398T3 (da) * | 2016-02-05 | 2024-06-24 | Orionis Biosciences BV | Målrettede terapeutiske midler og anvendelse heraf |
WO2017177175A1 (en) * | 2016-04-07 | 2017-10-12 | The George Washington University | Methods and compositions targeting retroviral latency |
KR20220148306A (ko) | 2016-05-27 | 2022-11-04 | 알토 바이오사이언스 코포레이션 | Cd3 결합 도메인을 가지는 다량체 il-15 기반 분자의 구성 및 특성규명 |
SG11201810332TA (en) | 2016-05-27 | 2018-12-28 | Etubics Corp | Neoepitope vaccine compositions and methods of use thereof |
AU2017290803A1 (en) * | 2016-06-30 | 2019-01-24 | Nant Holdings Ip, Llc | Nant cancer vaccine |
PE20191034A1 (es) | 2016-10-14 | 2019-08-05 | Xencor Inc | Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15r y fragmentos de anticuerpo pd-1 |
WO2018081830A1 (en) * | 2016-10-31 | 2018-05-03 | Oregon Health & Science University | Combinations of agents to treat hematological malignancies |
WO2018134784A1 (en) * | 2017-01-20 | 2018-07-26 | Novartis Ag | Combination therapy for the treatment of cancer |
CN110177568A (zh) * | 2017-01-20 | 2019-08-27 | 诺华股份有限公司 | 用于治疗癌症的组合疗法 |
US10440535B2 (en) | 2017-01-25 | 2019-10-08 | The George Washington University | System and method for asset-agnostic wireless monitoring and predictive maintenance of deployed assets |
US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
KR20230170821A (ko) | 2017-03-06 | 2023-12-19 | 알토 바이오사이언스 코포레이션 | Il-12 및 il-18로의 il-15-기반 융합 |
US20190048055A1 (en) | 2017-03-31 | 2019-02-14 | Altor Bioscience Corporation | Alt-803 in combination with anti-cd38 antibody for cancer therapies |
EP3621647A1 (en) * | 2017-05-11 | 2020-03-18 | Nantkwest, Inc. | Anti-egfr/high affinity nk-cells compositions and methods for chordoma treatment |
CA3063735A1 (en) * | 2017-05-26 | 2018-11-29 | Etubics Corporation | Combination immunotherapies comprising il-15 superagonists |
AU2018291497A1 (en) | 2017-06-30 | 2020-01-16 | Xencor, Inc. | Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains |
CN108070556A (zh) * | 2017-07-26 | 2018-05-25 | 深圳市北科生物科技有限公司 | 用于免疫细胞培养的方法和组合物 |
WO2019090134A1 (en) * | 2017-11-03 | 2019-05-09 | Precision Biologics, Inc. | Monoclonal antibody neo-201 for the treatment of human carcinomas |
US20190241665A1 (en) * | 2018-01-25 | 2019-08-08 | Wisconsin Alumni Research Foundation | Methods of inhibiting metastasis in cancer |
CN111836639A (zh) | 2018-01-26 | 2020-10-27 | 河谷细胞有限公司 | 用于联合癌症疫苗和免疫辅助疗法的组合物和方法 |
EP3759144A1 (en) * | 2018-03-01 | 2021-01-06 | Glycotope GmbH | Fusion protein constructs comprising an anti-muc1 antibody and il-15 |
CN111867612A (zh) * | 2018-03-26 | 2020-10-30 | 阿尔托生物科学有限责任公司 | 抗PDL1、IL-15和TGF-β受体组合分子 |
US11524991B2 (en) | 2018-04-18 | 2022-12-13 | Xencor, Inc. | PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof |
CA3097741A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains |
JP7516254B2 (ja) * | 2018-04-18 | 2024-07-16 | ゼンコア インコーポレイテッド | Il-15/il-15raヘテロ二量体fc融合タンパク質およびその使用 |
US11564980B2 (en) | 2018-04-23 | 2023-01-31 | Nantcell, Inc. | Tumor treatment method with an individualized peptide vaccine |
TW202345890A (zh) * | 2018-04-23 | 2023-12-01 | 美商南特細胞公司 | 新抗原表位疫苗及免疫刺激組合物及方法 |
WO2019207942A1 (ja) * | 2018-04-27 | 2019-10-31 | OTA Takayo | 免疫チェックポイント阻害剤によるがん治療の効果を評価するためのバイオマーカー |
US11134120B2 (en) | 2018-05-18 | 2021-09-28 | Inveniam Capital Partners, Inc. | Load balancing in blockchain environments |
SG11202010496WA (en) | 2018-05-18 | 2020-12-30 | Daiichi Sankyo Co Ltd | Anti-muc1 antibody-drug conjugate |
US11701408B2 (en) * | 2018-10-11 | 2023-07-18 | Nantcell, Inc. | Treatment of immunosuppressed subjects |
MA53862A (fr) | 2018-10-12 | 2022-01-19 | Xencor Inc | Protéines de fusion fc d'il-15/il-15ralpha ciblant pd-1 et utilisations dans des polythérapies faisant intervenir celles-ci |
KR20210090203A (ko) * | 2018-11-09 | 2021-07-19 | 넥타르 테라퓨틱스 | 또 다른 약리학적 활성제와 조합된 지속 작용성 인터류킨-15 수용체 효현제 |
MX2021006589A (es) * | 2018-12-13 | 2021-07-07 | Jiangsu Hengrui Medicine Co | Uso de un complejo de proteinas il-15 junto con un anticuerpo contra pd-l1 para el tratamiento de enfermedades tumorales. |
CN113438961A (zh) | 2018-12-20 | 2021-09-24 | Xencor股份有限公司 | 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白 |
US20220106375A1 (en) * | 2019-01-11 | 2022-04-07 | Memorial Sloan Kettering Cancer Center | Multimerization of il-15/il-15r-alpha-fc complexes to enhance immunotherapy |
WO2020231855A1 (en) | 2019-05-10 | 2020-11-19 | Nant Holdings Ip, Llc | Nogapendekin alfa-inbakicept for immune stimulant therapies and treatment of viral infections |
CA3117134A1 (en) * | 2019-07-08 | 2021-01-14 | Nantkwest, Inc. | Ciml nk cells and methods therefor |
EP4021928A4 (en) * | 2019-08-29 | 2023-09-20 | NantBio, Inc. | MODIFIED N-810 AND ASSOCIATED METHODS |
BR112022004712A2 (pt) * | 2019-09-16 | 2022-06-14 | Gt Biopharma Inc | Compostos e métodos de imunoterapia |
RU2753282C2 (ru) * | 2019-09-19 | 2021-08-12 | Закрытое Акционерное Общество "Биокад" | ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ |
TW202128757A (zh) | 2019-10-11 | 2021-08-01 | 美商建南德克公司 | 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白 |
US20210188933A1 (en) * | 2019-12-18 | 2021-06-24 | Nantcell, Inc | Methods of treating pancytopenia |
EP4188418A1 (en) | 2020-08-03 | 2023-06-07 | Nantcell, Inc. | Drug-specific pharmacokinetic assay for il-15 superagonist |
WO2022140701A1 (en) * | 2020-12-24 | 2022-06-30 | Xencor, Inc. | Icos targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and icos antigen binding domains |
CN113321736B (zh) * | 2020-12-30 | 2024-01-09 | 苏州复融生物技术有限公司 | 一种长效化白介素15融合蛋白及其制备方法和应用 |
WO2022192259A1 (en) * | 2021-03-09 | 2022-09-15 | Cureimmune Therapeutics Inc. | BIFUNCTIONAL HOMODIMERIC ANTI-PD-1 AND IL-15/IL-15Rα FUSION PROTEINS AND USES THEREOF |
CN116655771A (zh) * | 2021-05-28 | 2023-08-29 | 苏州复融生物技术有限公司 | 一种新型白介素15突变体多肽的开发及其应用 |
WO2022260849A1 (en) | 2021-06-09 | 2022-12-15 | Nant Holdings Ip, Llc | Methods and systems for producing a protein of interest in a plant |
WO2024137136A1 (en) * | 2022-12-22 | 2024-06-27 | University Of Houston System | Inhibitors of il-15 and their use in treating or preventing sepsis, severe sepsis and septic shock |
WO2024199355A1 (en) * | 2023-03-29 | 2024-10-03 | Starna Therapeutics | Nucleic acids encoding therapeutic polypeptides and lipid nanoparticle composition comprising the nucleic acids |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1975A (en) | 1841-02-12 | Manner of constructing corn-shellers | ||
US222A (en) | 1837-06-10 | Truss for the retention and radical cure qe hernia | ||
US8507A (en) | 1851-11-11 | petess | ||
JPS551222Y2 (es) | 1975-10-07 | 1980-01-14 | ||
JPS551222U (es) | 1978-06-15 | 1980-01-07 | ||
JPS5841623Y2 (ja) | 1980-06-19 | 1983-09-20 | ミツミ電機株式会社 | デイテント式スライドスイツチ装置 |
JPS5718916A (en) | 1980-07-11 | 1982-01-30 | Iseki Agricult Mach | Shaking table sorter of automatic feeding type thresher |
JPS5770185A (en) | 1980-10-21 | 1982-04-30 | Kazuo Makino | Preparation of blended oil for coal liquefaction |
JPS57144287A (en) | 1981-03-02 | 1982-09-06 | Toray Ind Inc | Cyclopentabenzofuran derivative |
JPS5841623U (ja) | 1981-09-17 | 1983-03-18 | 日産デイ−ゼル工業株式会社 | リアエンジンバスにおけるエンジンル−ムの冷却及び房内熱風排出装置 |
JPS6152156U (es) | 1984-09-12 | 1986-04-08 | ||
JPS6251570U (es) | 1985-09-18 | 1987-03-31 | ||
JPS648039U (es) | 1987-06-29 | 1989-01-17 | ||
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
US5288931A (en) * | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
AU5098393A (en) | 1992-08-14 | 1994-03-15 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Recombinant toxin with increased half-life |
US5747654A (en) | 1993-06-14 | 1998-05-05 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant disulfide-stabilized polypeptide fragments having binding specificity |
JPH09512165A (ja) | 1994-04-06 | 1997-12-09 | イミュネックス・コーポレーション | インターロイキン15 |
NZ266264A (en) | 1994-04-06 | 1997-01-29 | Immunex Corp | Mammalian epithelium-derived t-cell factor called interleukin-15 |
US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
US7008624B1 (en) | 1995-02-22 | 2006-03-07 | Immunex Corporation | Antagonists of interleukin-15 |
US5795966A (en) | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5534592A (en) | 1995-09-22 | 1996-07-09 | The Goodyear Tire & Rubber Company | High performance blend for tire treads |
EP0904107B1 (en) | 1996-03-18 | 2004-10-20 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US6001973A (en) | 1996-04-26 | 1999-12-14 | Beth Israel Deaconess Medical Center | Antagonists of interleukin-15 |
DE69830257T3 (de) | 1997-02-21 | 2009-10-15 | Amgen Inc., Thousand Oaks | Verwendung von Interleukin-15 |
GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
WO2001056387A1 (en) | 2000-02-01 | 2001-08-09 | Donnell Michael A O | Immunotherapeutic treatment methodology for patients afflicted with superficial bladder cancer who previously failed at least one immunostimulatory therapeutic treatment regimen |
AU6158501A (en) | 2000-05-12 | 2001-11-26 | Beth Israel Hospital | Compositions and methods for achieving immune suppression |
CN101712721A (zh) | 2000-06-05 | 2010-05-26 | 阿尔托生物科学有限公司 | T细胞受体融合物及共轭物以及其使用方法 |
DE60138222D1 (de) | 2000-09-14 | 2009-05-14 | Beth Israel Hospital | Modulierung von il-2 und il-15 vermittelten t zellantworten |
US20030180888A1 (en) | 2000-11-03 | 2003-09-25 | Millennium Pharmaceuticals, Inc. | CD2000 and CD2001 molecules, and uses thereof |
JP2003026599A (ja) * | 2001-06-11 | 2003-01-29 | Univ Nagoya | Il−15遺伝子を応用したワクチンアジュバント |
FI117667B (fi) * | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
KR100708398B1 (ko) | 2002-03-22 | 2007-04-18 | (주) 에이프로젠 | 인간화 항체 및 이의 제조방법 |
WO2004028339A2 (en) | 2002-09-27 | 2004-04-08 | Brigham And Women's Hospital, Inc. | Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues |
CN1852732A (zh) * | 2002-12-26 | 2006-10-25 | 山景医药公司 | 具有增强的生物学效用的干扰素-β的聚合物缀合物 |
EA015897B1 (ru) | 2003-02-26 | 2011-12-30 | Генмаб А/С | Применение человеческого моноклонального антитела к ил-15 в составе композиции и лекарственного препарата (варианты), композиция и лекарственный препарат, его включающие |
DE10324708A1 (de) | 2003-05-30 | 2004-12-16 | Ltn Servotechnik Gmbh | Schleifringelement und Verfahren zu dessen Herstellung |
CN1233822C (zh) | 2003-09-05 | 2005-12-28 | 中国科学技术大学 | 白细胞介素-15基因修饰的自然杀伤细胞株及其制备方法 |
EP1691661B1 (en) | 2003-11-10 | 2014-01-08 | Altor BioScience Corporation | Soluble tcr molecules and methods of use |
ATE516305T1 (de) | 2004-02-27 | 2011-07-15 | Inst Nat Sante Rech Med | Il-15-bindungsstelle für il-15-ralpha und spezifische il-15-mutanten mit wirkung als agonisten/antagonisten |
EP1586585A1 (de) | 2004-04-14 | 2005-10-19 | F. Hoffmann-La Roche Ag | Expressionssystem zur Herstellung von IL-15/Fc-Fusionsproteinen und ihre Verwendung |
CN100334112C (zh) | 2004-10-15 | 2007-08-29 | 上海海欣生物技术有限公司 | 人白细胞介素15与Fc融合蛋白 |
LT1814580T (lt) | 2004-11-24 | 2016-12-12 | Fred Hutchinson Cancer Research Center | Il 21 naudojimo pritaikomajai imunoterapijai ir naviko antigenų identifikavimo metodai |
RU2007126553A (ru) | 2004-12-13 | 2009-01-20 | Цитос Биотехнологи Аг (Ch) | Упорядоченные ряды антигенов ил-15 и их применение |
AU2011203119C1 (en) * | 2005-05-09 | 2018-06-14 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
NZ581779A (en) | 2005-05-17 | 2011-09-30 | Univ Connecticut | Composition and methods for immunomodulation in an organism comprising interleukin-15 polypeptide and interleukin-15 receptor subunit A polypeptide complex |
EP1777294A1 (en) | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
DE602006016765D1 (de) | 2006-06-30 | 2010-10-21 | Conaris Res Inst Ag | Verbesserte sgp 130Fc Dimere |
US7965180B2 (en) | 2006-09-28 | 2011-06-21 | Semiconductor Energy Laboratory Co., Ltd. | Wireless sensor device |
CA2682527C (en) | 2007-03-30 | 2017-07-11 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes |
ES2470772T3 (es) | 2007-05-11 | 2014-06-24 | Altor Bioscience Corporation | Moléculas de fusión y variantes de IL-15 |
AU2013273643C1 (en) | 2007-05-11 | 2016-08-11 | Altor Bioscience Corporation | Fusion molecules and il-15 variants |
AU2008279550B2 (en) | 2007-06-21 | 2012-08-09 | Angelica Therapeutics, Inc. | Modified toxins |
AU2008269032B2 (en) | 2007-06-27 | 2013-12-05 | Novartis Ag | Complexes of IL-15 and IL-15Ralpha and uses thereof |
US20110070191A1 (en) | 2008-03-19 | 2011-03-24 | Wong Hing C | T cell receptor fusions and conjugates and methods of use there of |
ES2363358B1 (es) * | 2009-04-03 | 2012-06-21 | FUNDACIÓ INSTITUT DE RECERCA HOSPITAL UNIVERSITARI VALL D'HEBRON (Titular al | Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable. |
US11053299B2 (en) | 2010-09-21 | 2021-07-06 | Immunity Bio, Inc. | Superkine |
CN107880136B (zh) | 2010-09-21 | 2021-11-12 | 阿尔托生物科学有限公司 | 多聚体il-15可溶性融合分子与其制造与使用方法 |
US9732143B2 (en) * | 2011-02-03 | 2017-08-15 | Xoma Technology Ltd. | Methods and materials for enhancing functional protein expression in bacteria |
EP2537933A1 (en) | 2011-06-24 | 2012-12-26 | Institut National de la Santé et de la Recherche Médicale (INSERM) | An IL-15 and IL-15Ralpha sushi domain based immunocytokines |
US20130302274A1 (en) * | 2011-11-25 | 2013-11-14 | Roche Glycart Ag | Combination therapy |
US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
WO2014028776A1 (en) | 2012-08-15 | 2014-02-20 | Zyngenia, Inc. | Monovalent and multivalent multispecific complexes and uses thereof |
EP2911684B1 (en) * | 2012-10-24 | 2019-06-19 | Novartis Ag | Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes |
PL3094351T3 (pl) | 2014-01-15 | 2022-06-27 | Kadmon Corporation, Llc | Środki immunomodulujące |
AU2015284248B2 (en) | 2014-06-30 | 2020-04-16 | Altor Bioscience Corporation | IL-15-based molecules and methods of use thereof |
CN104672325A (zh) | 2015-03-11 | 2015-06-03 | 福建农林大学 | 一种用新鲜螺旋藻制备藻蓝蛋白的方法 |
WO2017053649A1 (en) | 2015-09-25 | 2017-03-30 | Altor Bioscience Corporation | Interleukin-15 superagonist significantly enhances graft-versus-tumor activity |
KR20220148306A (ko) | 2016-05-27 | 2022-11-04 | 알토 바이오사이언스 코포레이션 | Cd3 결합 도메인을 가지는 다량체 il-15 기반 분자의 구성 및 특성규명 |
CN118562016A (zh) | 2016-10-21 | 2024-08-30 | 艾尔特生物科技公司 | 基于多聚体il-15的分子 |
CN111867612A (zh) | 2018-03-26 | 2020-10-30 | 阿尔托生物科学有限责任公司 | 抗PDL1、IL-15和TGF-β受体组合分子 |
-
2015
- 2015-06-30 AU AU2015284248A patent/AU2015284248B2/en active Active
- 2015-06-30 JP JP2016575844A patent/JP6842926B2/ja active Active
- 2015-06-30 EP EP15815782.6A patent/EP3160498B1/en active Active
- 2015-06-30 EP EP20152694.4A patent/EP3673915A1/en active Pending
- 2015-06-30 KR KR1020237005025A patent/KR20230028807A/ko not_active Application Discontinuation
- 2015-06-30 KR KR1020217022404A patent/KR102503476B1/ko active IP Right Grant
- 2015-06-30 CN CN202011477829.2A patent/CN112494646A/zh active Pending
- 2015-06-30 KR KR1020177002560A patent/KR102398246B1/ko active IP Right Grant
- 2015-06-30 CA CA2953816A patent/CA2953816C/en active Active
- 2015-06-30 MX MX2017000116A patent/MX2017000116A/es unknown
- 2015-06-30 ES ES15815782T patent/ES2899890T3/es active Active
- 2015-06-30 CN CN202110724454.3A patent/CN113384686A/zh active Pending
- 2015-06-30 WO PCT/US2015/038587 patent/WO2016004060A2/en active Application Filing
- 2015-06-30 PL PL15815782T patent/PL3160498T3/pl unknown
- 2015-06-30 CA CA3151221A patent/CA3151221A1/en active Pending
- 2015-06-30 CN CN201580046144.3A patent/CN106659775B/zh active Active
- 2015-06-30 EP EP21173707.7A patent/EP3912637A1/en active Pending
- 2015-06-30 US US14/755,989 patent/US9925247B2/en active Active
-
2018
- 2018-03-14 US US15/921,512 patent/US10537615B2/en active Active
-
2019
- 2019-06-18 US US16/444,807 patent/US11173191B2/en active Active
-
2020
- 2020-04-23 JP JP2020076412A patent/JP2020128390A/ja not_active Withdrawn
- 2020-07-01 AU AU2020204408A patent/AU2020204408B2/en active Active
- 2020-07-09 US US16/925,138 patent/US11471511B2/en active Active
-
2021
- 2021-07-21 JP JP2021120881A patent/JP2021176880A/ja active Pending
-
2022
- 2022-03-14 AU AU2022201758A patent/AU2022201758B2/en active Active
- 2022-05-26 US US17/825,959 patent/US11679144B2/en active Active
- 2022-10-11 US US18/045,572 patent/US11992516B2/en active Active
- 2022-12-09 US US18/063,871 patent/US11890323B2/en active Active
-
2023
- 2023-02-27 US US18/175,112 patent/US11925676B2/en active Active
- 2023-02-28 US US18/176,196 patent/US20230241175A1/en active Pending
- 2023-03-10 JP JP2023037991A patent/JP7561905B2/ja active Active
- 2023-12-22 US US18/394,409 patent/US12097244B2/en active Active
-
2024
- 2024-04-18 US US18/639,678 patent/US20240252591A1/en active Pending
- 2024-04-18 US US18/639,659 patent/US20240261373A1/en active Pending
- 2024-05-30 US US18/678,987 patent/US20240299498A1/en active Pending
- 2024-06-07 US US18/737,455 patent/US20240307494A1/en active Pending
- 2024-06-07 US US18/737,465 patent/US20240307495A1/en active Pending
- 2024-07-18 AU AU2024204957A patent/AU2024204957A1/en active Pending
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11498950B1 (en) | 2007-05-11 | 2022-11-15 | Altor Bioscience, Llc | Fusion molecules and IL-15 variants |
US11365231B2 (en) | 2007-05-11 | 2022-06-21 | Altor Bioscience, Llc | Interleukin 15 (IL-15) variants |
US11673932B2 (en) | 2007-05-11 | 2023-06-13 | Altor BioScience, LLC. | Fusion molecules and IL-15 variants |
US11053299B2 (en) | 2010-09-21 | 2021-07-06 | Immunity Bio, Inc. | Superkine |
US11104716B2 (en) | 2010-09-21 | 2021-08-31 | Altor BioScience, LLC. | Multimeric IL-15 soluble fusion molecules and methods of making and using same |
US11046747B2 (en) | 2010-09-21 | 2021-06-29 | Altor Bioscience Llc | Multimeric IL-15 soluble fusion molecules and methods of making and using same |
US11845783B2 (en) | 2010-09-21 | 2023-12-19 | Altor BioScience, LLC. | Multimeric IL-15 soluble fusion molecules and methods of making and using same |
US11890323B2 (en) | 2014-06-30 | 2024-02-06 | Altor Bioscience, Llc | Method of treating cancer with composition comprising IL-15-based molecules and BCG |
US11471511B2 (en) | 2014-06-30 | 2022-10-18 | Altor Bioscience, Llc | IL-15-based molecules and methods of use thereof |
US11679144B2 (en) | 2014-06-30 | 2023-06-20 | Altor BioScience, LLC. | IL-15-based molecules and methods of use thereof |
US11173191B2 (en) | 2014-06-30 | 2021-11-16 | Altor BioScience, LLC. | IL-15-based molecules and methods of use thereof |
US11925676B2 (en) | 2014-06-30 | 2024-03-12 | Altor BioScience, LLC. | Method for treating neoplasia with an anti-CD38 antibody and an IL-15:IL-15R complex |
US11992516B2 (en) | 2014-06-30 | 2024-05-28 | Altor BioScience, LLC. | Compositions comprising IL-15-based molecules and immune checkpoint inhibitor antibodies |
US12097244B2 (en) | 2014-06-30 | 2024-09-24 | Altor BioScience, LLC. | Methods of treating a neoplasia with IL-15-based molecules and CTLA-4 antibody |
US11369679B2 (en) | 2016-10-21 | 2022-06-28 | Altor Bioscience, Llc | Multimeric IL-15-based molecules |
US11318201B2 (en) | 2016-10-21 | 2022-05-03 | Altor BioScience, LLC. | Multimeric IL-15-based molecules |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017000116A (es) | Moleculas basadas en il-15 y metodos para su uso. | |
JOP20200192A1 (ar) | أجسام مضادة لـ tigit | |
PH12020550781A1 (en) | Anti-jagged1 antibodies and methods of use | |
NZ731467A (en) | Anti-tim3 antibodies and methods of use | |
PH12017500877A1 (en) | ANTI-CD79b ANTIBODIES AND METHODS OF USE | |
PH12016501894A1 (en) | Anti-ox40 antibodies and methods of use | |
PH12016501618A1 (en) | Anti-dll3 antibodies and drug conjugates for use in melanoma | |
MX2020002694A (es) | Moleculas de anticuerpo que se unen a tim-3 y usos de las mismas. | |
MX2017003022A (es) | Anticuerpos anti-cll-1 e inmunoconjugados. | |
MX2015012326A (es) | Anticuerpos anti-crth2 y su uso. | |
PH12017500406A1 (en) | Novel anti-mfi2 antibodies and methods of use | |
PH12016502061A1 (en) | Novel antii-rnf43 antibodies and methods of use | |
MX2019005299A (es) | Anticuerpos anti-receptor del factor de crecimiento de tipo insulinico humano 1 (anti-igf-1r) con abolicion de la union al fcrn y su uso en el tratamiento de enfermedades oculares vasculares. | |
MX2016015280A (es) | Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso. | |
NZ744340A (en) | Anti-jagged1 antibodies and methods of use |